Publications by authors named "Daniel Thomas Jones"

Claim this Profile
A
Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions.
Matthew Rubinstein, Madeline Lauren Hong, Rishi Kumar Nanda, Daniel Thomas Jones, Hazem Aboaid

Oncol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomere Dynamics in Cardiovascular Aging: From Molecular Mechanisms to Precision Medicine.
Abbas Mohammadi, Daniel Thomas Jones, Somayeh Mohammadi, Giv Heidari-Bateni, William H Frishman

Cardiol Rev· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances and challenges in immunotherapy in head and neck cancer.
Hazem Aboaid, Taimur Khalid, Abbas Hussain, Yin Mon Myat, Rishi Kumar Nanda, Daniel Thomas Jones

Front Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors.
Hazem Aboaid, Yin Mon Myat, Daniel Thomas Jones, Kyaw Zin Thein

Transl Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab.
Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Rishi Kumar Nanda

Explor Target Antitumor Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.
Daniel Thomas Jones, Abbas Hussain, Hazem Aboaid, Riccesha Hattin, Savannah Schauer

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.
Ramaditya Srinivasmurthy, Hazem Aboaid, Abbas Hussain, Riccesha Hattin, Savannah Schauer, Daniel Thomas Jones

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-198: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Hand-Foot Skin Reaction (HFSR) or Palmar-Plantar Erythrodysesthesia (PPE) in Patients With Cancers Treated With Fruquintinib.
Jason Ta, Benjamin Tzer-Ming Chuang, Hazem Aboaid, Daniel Thomas Jones, Ramaditya Srinivasmurthy

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs).
Ramaditya Srinivasmurthy, Hazem Aboaid, Daniel Thomas Jones, Kevin Nguyen, Jason Ta

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.
Riccesha Hattin, Abbas Hussain, Hazem Aboaid, Savannah Schauer, Tal Schlesinger, Daniel Thomas Jones

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.
Riccesha Hattin, Hazem Aboaid, Abbas Hussain, Savannah Schauer, Tal Schlesinger, Daniel Thomas Jones

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.
Riccesha Hattin, Hazem Aboaid, Abbas Hussain, Savannah Schauer, Tal Schlesinger, Daniel Thomas Jones

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-150: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Health-Related Quality of Life (HRQOL) Events in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated With First-Line Immunochemotherapy.
Rishi Kumar Nanda, Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy.
Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Jason Ta

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
Taimur Khalid, Hazem Aboaid, Daniel Thomas Jones, Jason Ta, Ramaditya Srinivasmurthy

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis